Form 4: Quest Diagnostics SVP & General Counsel Michael Prevoznik Reports Stock Transactions

Michael Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the disposition and acquisition of company stock, including sales under a Rule 10b5-1 plan and shares held in a 401(k)/SDCP.

Summary

• Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On February 19, 2025, 374 shares of common stock were disposed of to cover tax withholding obligations at a price of $169.71.
• On February 20, 2025, 604 shares of common stock were sold at a price of $170.99 under a Rule 10b5-1 sales plan.
• Prevoznik directly owns 39,845 shares of Quest Diagnostics common stock following these transactions.
• Additionally, Prevoznik indirectly owns 5,641 shares through the company's 401(k)/SDCP.
• The transactions were reported by Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions include both a sale for tax obligations and a sale under a pre-arranged plan, which doesn't necessarily indicate a negative outlook.

Industry Context

Executive stock transactions are routinely monitored by investors to gauge sentiment and potential future performance. Sales under a pre-arranged 10b5-1 plan are less indicative of immediate sentiment than discretionary trades.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders due to the relatively small number of shares involved.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Quest Diagnostics, DGX, Michael Prevoznik, Stock Transactions, Beneficial Ownership, Rule 10b5-1, 401(k), SDCP